Provided by Tiger Trade Technology Pte. Ltd.

INNOVENT BIO

99.100
-3.300-3.22%
Volume:8.28M
Turnover:829.56M
Market Cap:172.83B
PE:180.84
High:103.300
Open:103.200
Low:98.550
Close:102.400
52wk High:109.100
52wk Low:69.550
Shares:1.74B
HK Float Shares:1.74B
Volume Ratio:0.70
T/O Rate:0.47%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.548
ROE:5.01%
ROA:1.56%
PB:7.66
PE(LYR):180.84
PS:11.37

Loading ...

Innovent Biologics - Q1 2026 Total Product Revenue Exceeds RMB3.8 Bln, up Over 50% Y/Y

THOMSON REUTERS
·
Apr 30

Innovent Q1 product revenue tops RMB 3.8 billion, up over 50%

Reuters
·
Apr 30

信达生物(01801)2025年营收达人民币130.415亿元 首度实现全年盈利并巩固多元化创新药管线

Bulletin Express
·
Apr 28

Innovent Biologics releases 2025 ESG report

Reuters
·
Apr 28

INNOVENT BIO Maintains MSCI AAA Rating, Accelerates Carbon and Water Efficiency in 2025 ESG Report

Bulletin Express
·
Apr 28

Innovent Biologics publishes 2025 annual report

Reuters
·
Apr 28

Sino Biopharma appoints Kang Xiaoyan chief medical officer

Reuters
·
Apr 28

Bank of America Securities Maintains Buy Rating on Innovent Biologics with HK$116.8 Target

Stock News
·
Apr 28

INNOVENT BIO Shares Climb Over 4% in Afternoon Session Following Key Data Presentation

Stock News
·
Apr 24

Biopharma Stocks Slide Across Board as Oil Prices Squeeze Rate Cut Prospects

Stock News
·
Apr 23

Innovent advances IBI363 into phase 3 MarsLight-11 trial in squamous NSCLC

Reuters
·
Apr 22

Xie Zhiyu's Q1 Portfolio Revealed: Increased Bets on Chemical and Energy Storage Sectors

Stock News
·
Apr 21

CMB International Reports Moderate Recovery in Healthcare Sector Risk Appetite, Recommends Six Stocks Including Hansoh Pharma

Stock News
·
Apr 20

China International Capital Corporation: National Policy Optimizes Initial Pricing Mechanism for Innovative Drugs, Pharmaceutical Sector Set for High-Quality Development

Stock News
·
Apr 16

INNOVENT BIO Establishes New Pharmaceutical Firm in Shanghai

Deep News
·
Apr 15

Stock Track | Innovent Biologics Soars 5.04% Intraday on GLP-1 Weight-Loss Drug Approval

Stock Track
·
Apr 15

Assessing Innovent Biologics (SEHK:1801) Valuation After New IBI3055 Autoimmune Preclinical Data

Simply Wall St.
·
Apr 13

Innovent presents preclinical data on IBI3055 at Immune Resetting Summit 2026

Reuters
·
Apr 10

Immune Resetting: B-Cell Mediated & Beyond Summit 2026 Oral Presentation: Innovent Biologics Announces Pre-Clinical Results of Ibi3055, a Tri-Specific T Cell Engager Targeting Autoimmune Diseases

THOMSON REUTERS
·
Apr 10

Interview with Xellar Technology's Xie Xin: Organ-on-a-Chip Commercialization Gains Momentum as Pharma Pays to Reduce R&D Uncertainty and Failure Risks

Deep News
·
Apr 08